This project has been flagged by a community member as inappropriate due to reason below.*
Slingshot & STAT have partnered to provide you with interviews with experts led by STAT's reporters. This call is on:

Peanut allergy treatments: What’s next for the field?

Ticker(s): AIMT, DBVT

Who's the expert?

Name: Dr Erwin Gelfand - MD

Institution: National Jewish Health

  • Pediatric allergist and immunologist and Professor of Pediatrics at National Jewish Health in Denver.
  • Follows hundreds of patients with peanut allergy at his center; has researched and published on peanut allergy, and is very familiar with the competing interests of Aimmune (AR-101) and Viaskin patch.
  • Clinical interests include the diagnosis and treatment of immune deficiency and autoimmune disorders and severe atopic diseases; has received numerous grants from the National Institutes of Health, the Environmental Protection Agency and several foundations, and has published more than 750 papers in peer-reviewed journals.

Interview Questions
Q1.

Question from the STAT Reporting Team to Come!

Added By: joe_mccann
Q2.

Given the emerging evidence potentially linking microbiome and food allergy (preventative and therapeutic), is it known if any patients take probiotics in the pivotal studies for AIMT and DBVT (controlled or not) and if the usage of probiotics had any impact on safety or efficacy? And could there be a rationale to take OTC probiotics to improve safety/efficacy profile for either of the products, especially AR101?

Added By: homer
Q3.

The AR101 protocol call for 5 updoses on the first day, with a minimum 30 minutes separating each dose, and if a patient has an AE, at least 60 minutes separating the doses. This seems to roughly equate to 5 hours of clinic time to treat a patient. How would a practice with limited room manage this? Community waiting room or occupy a single room? Will this create a bottleneck to treat patients?

Added By: trip
Q4.

As a follow up, as reported by AIMT in NEJM publication on the PALISADE study, 50% of patients experience an AE on the initiation of therapy. 22% of these children experience abdominal pain on the first day of therapy. How would you characterize these AE's in light of the fact that 20% of AR101 patients withdraw from their studies? How would this translate to real world practice?

Added By: trip
Q5.

Please ask Dr. Gelfand his thoughts on the "homebrew" practitioners using off the shelf peanut flour and various protocols. These practices also charge $4-$5k. 

There are approximately 400 "homebrew allergists". 

Added By: trip

Are You Interested In These Questions?



Expert research benefits investors by giving them timely access to unbiased real world perspectives on highly specialized topics. Slingshot Insights' crowdfunded model makes this access available at a fraction of the cost of other expert networks.

Reason

*Slingshot Insights provides access to information, not investment advice. We work to support you and facilitate access to experts; however we are not responsible for monitoring calls for the disclosure of MNPI. You should obtain financial, legal and tax advice from your qualified and licensed advisers before deciding to invest in any security.